Epigenetics Press Releases

Everyone wants to be healthy. It's clear that health and happiness strongly correlate and health advice is everywhere.

K WAVe 6 Radio is becoming more proactive with its internet presence.

BPS Bioscience, Inc. (“BPS”) announces new kits for screening inhibitors of the histone demethylases FBXL10 & FBXL11 and the histone methyltransferase SETDB1. These unique kits join a large portfolio of kits and proteins for epigenetic research.

Drug Discovery Teams to Unite for 3 Days of Learning & Collaboration - Free Passes Provide Access to Keynote Presentations by Chas Bountra, Martin Tolar, Andrew Hopkins and an Expansive Exhibit Hall

Highlighting the interplay between the genome-epigenome-disease

Constance, Germany – GATC Biotech launches its InView™ 2-weeks Exome service and enhanced, customised epigenetic support for its more than 10,000 clients.

tebu-bio is pleased to announce their agreement with EpiCypher™ to distribute their innovative product range throughout Europe

BioVision is very excited to announce the launch of the first edition of this latest brochure titled: “Epigenetics Research Tools”.

First commercially available NSD kits for inhibitor screening and profiling applications

Announcing the Availability of Methyl-Lysine Reader Proteins and Assay Kits for a New Class of Epigenetic Drug...

BPS Bioscience, Inc. (“BPS”) announced the addition of 3 new assay kits (BRD9, CREBBP, and TRIM24) for identifying small molecule inhibitors of bromodomains (BRDs).

Zymo Research offers genome-wide Next-Gen sequencing services for genetic, epigenetic, and expression analysis

BioVision recently introduced Nexturastat A, a highly potent and selective Histone Deacetylase 6 (HDAC6) inhibitor. This unique inhibitor is currently being marketed for research purposes exclusively by BioVision.

Anti-5-Methylcyidine from Clone 33D3 can be used in applications such as Methylated DNA Immunoprecipitation (MeDIP), MeDIP-on-chip assay, immunofluorescence, flow cytometry and immunohistochemistry

tebu-bio is pleased to announce their agreement with CH3 BioSystems to distribute their product range to the European market.

Bromodomains are a new emerging class of pharmaceutical targets in the field of Epigenetics. Bromodomains (BRDs) are protein domains involved in Epigenetics that recognize acetylated lysines.

Deoxyribonuclease I (DNAse I) is an endonuclease that cleaves DNA phosphodiester bonds. DNAse I targets single-stranded DNA, double-stranded DNA, and chromatin in a non-specific manner.

Methyltransferases are a diverse group of enzymes that methylate proteins, DNA, and small molecule targets. Accordingly, methyl transferase activity plays a critical role in modulating gene transcription, protein interactions, and signaling networks.

Everyone wants to be healthy. It's clear that health and happiness strongly correlate and health advice is everywhere.

K WAVe 6 Radio is becoming more proactive with its internet presence.

TET1 antibody for ICC/IF, IHC, IHC-P, WB and ChIP Assay. N3C1 polyclonal.

Immunotherapeutic approaches to cancer treatment continue to generate great interest. In an excellent Nature Reviews Cancer "Perspectives" discussion, Coulie et.al.

BPS Bioscience, Inc. (“BPS”) announces new kits for screening inhibitors of the histone demethylases FBXL10 & FBXL11 and the histone methyltransferase SETDB1. These unique kits join a large portfolio of kits and proteins for epigenetic research.

Drug Discovery Teams to Unite for 3 Days of Learning & Collaboration - Free Passes Provide Access to Keynote Presentations by Chas Bountra, Martin Tolar, Andrew Hopkins and an Expansive Exhibit Hall

Highlighting the interplay between the genome-epigenome-disease

A new report by visiongain calculates that the Alzheimer’s Disease Therapeutics and Diagnostics market will reach $7.0bn in 2014 with revenue showing strong overall growth to 2024, particularly beyond 2018.

Constance, Germany – GATC Biotech launches its InView™ 2-weeks Exome service and enhanced, customised epigenetic support for its more than 10,000 clients.

tebu-bio is pleased to announce their agreement with EpiCypher™ to distribute their innovative product range throughout Europe

BioVision is very excited to announce the launch of the first edition of this latest brochure titled: “Epigenetics Research Tools”.

First commercially available NSD kits for inhibitor screening and profiling applications

Led by global industry pioneers, Clinical Genomics & Informatics Europe will provide research teams with technologies and strategies for Exome Sequencing, High-Scale Computing, RNA Sequencing, Genome Informatics, Epigenetics and Digital Detection.

Announcing the Availability of Methyl-Lysine Reader Proteins and Assay Kits for a New Class of Epigenetic Drug...

BPS Bioscience, Inc. (“BPS”) announced the addition of 3 new assay kits (BRD9, CREBBP, and TRIM24) for identifying small molecule inhibitors of bromodomains (BRDs).

Zymo Research offers genome-wide Next-Gen sequencing services for genetic, epigenetic, and expression analysis

ReportReserve announces the inclusion of its new report published by Global Kalorama Information.

BioVision recently introduced Nexturastat A, a highly potent and selective Histone Deacetylase 6 (HDAC6) inhibitor. This unique inhibitor is currently being marketed for research purposes exclusively by BioVision.

Anti-5-Methylcyidine from Clone 33D3 can be used in applications such as Methylated DNA Immunoprecipitation (MeDIP), MeDIP-on-chip assay, immunofluorescence, flow cytometry and immunohistochemistry

tebu-bio is pleased to announce their agreement with CH3 BioSystems to distribute their product range to the European market.

Bromodomains are a new emerging class of pharmaceutical targets in the field of Epigenetics. Bromodomains (BRDs) are protein domains involved in Epigenetics that recognize acetylated lysines.

Jus International is holding a unique event -- A Blueprint for Abundant Living -- being held at Boston’s Marriott Copley Hotel on January 15, 2011, at 7 p.m.

AnaSpec, Eurogentec Group is pleased to offer anti-5-methylcytidine (Clone 33D3), Eurogentec’s most popular monoclonal antibody, for use in epigenetics research.

AbboMax offers nine novel anti- histone H3 antibodies specific for a mono-, di-, or tri-methylated state of Lys4, Lys9, and Lys27 for the epigenetics research. .

CHI’s makes available its Insight Pharma Report on current and projected markets for epigenetic diagnostic and therapeutic products.

Increasing numbers of research studies clearly demonstrate that genetics alone cannot explain the diversity of living organisms, reports Genetic Engineering & Biotechnology News (GEN).

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report that presents information about the quickly emerging worldwide epigenetics market.